FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079267672> ?p ?o ?g. }

• W2079267672 endingPage "247" @default.
• W2079267672 startingPage "244" @default.
• W2079267672 abstract "Background The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival. Methods Fifty-seven consecutive patients were treated with implanted HAI pumps and received a regimen of alternating floxuridine (0.1 mg/kg/day continuous HAI for 7 days) followed by a weekly HAI pump bolus of 5-fluorouracil (15 mg/kg for 3 weeks). Any changes in treatment plan because of toxicity, antitumor response, and survival were recorded. Results Thirty-one (54.4%) patients responded to this HAI regimen; 14 (24.5%) patients had stable disease, and 12 (21.1%) progressed during treatment. Responders or patients with stable disease had a significantly (P < 0.05) improved survival rate (19 months median) compared with patients in whom disease progressed (12 months median). Two (3.5%) patients developed biliary sclerosis and 12 (21.1%) had mild transient liver function abnormalities. The liver alone or in combination with another area was the site of first progression of disease in 40 (70.2%) patients. Conclusions This regimen had reversible or no hepatobiliary toxicity in more than 95% of patients. Tumor reduction or stabilization of disease was observed in 79% of the patients, who had a median survival of 19 months. Reduced toxicity and more effective chemotherapeutic regimens may increase the likelihood of survival after HAI chemotherapy for unresectable colorectal liver métastases. The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival. Fifty-seven consecutive patients were treated with implanted HAI pumps and received a regimen of alternating floxuridine (0.1 mg/kg/day continuous HAI for 7 days) followed by a weekly HAI pump bolus of 5-fluorouracil (15 mg/kg for 3 weeks). Any changes in treatment plan because of toxicity, antitumor response, and survival were recorded. Thirty-one (54.4%) patients responded to this HAI regimen; 14 (24.5%) patients had stable disease, and 12 (21.1%) progressed during treatment. Responders or patients with stable disease had a significantly (P < 0.05) improved survival rate (19 months median) compared with patients in whom disease progressed (12 months median). Two (3.5%) patients developed biliary sclerosis and 12 (21.1%) had mild transient liver function abnormalities. The liver alone or in combination with another area was the site of first progression of disease in 40 (70.2%) patients. This regimen had reversible or no hepatobiliary toxicity in more than 95% of patients. Tumor reduction or stabilization of disease was observed in 79% of the patients, who had a median survival of 19 months. Reduced toxicity and more effective chemotherapeutic regimens may increase the likelihood of survival after HAI chemotherapy for unresectable colorectal liver métastases." @default.
• W2079267672 created "2016-06-24" @default.
• W2079267672 creator A5024142413 @default.
• W2079267672 creator A5029283529 @default.
• W2079267672 creator A5032337653 @default.
• W2079267672 creator A5042809748 @default.
• W2079267672 creator A5064488553 @default.
• W2079267672 creator A5075794528 @default.
• W2079267672 creator A5091003529 @default.
• W2079267672 date "1996-09-01" @default.
• W2079267672 modified "2023-09-25" @default.
• W2079267672 title "Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity" @default.
• W2079267672 cites W1835268604 @default.
• W2079267672 cites W1986924507 @default.
• W2079267672 cites W1992676015 @default.
• W2079267672 cites W1998966672 @default.
• W2079267672 cites W2008963397 @default.
• W2079267672 cites W2016575308 @default.
• W2079267672 cites W2083616014 @default.
• W2079267672 cites W2128813634 @default.
• W2079267672 cites W2221252789 @default.
• W2079267672 doi "https://doi.org/10.1016/s0002-9610(96)00159-6" @default.
• W2079267672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8862076" @default.
• W2079267672 hasPublicationYear "1996" @default.
• W2079267672 type Work @default.
• W2079267672 sameAs 2079267672 @default.
• W2079267672 citedByCount "35" @default.
• W2079267672 countsByYear W20792676722012 @default.
• W2079267672 countsByYear W20792676722014 @default.
• W2079267672 countsByYear W20792676722016 @default.
• W2079267672 countsByYear W20792676722017 @default.
• W2079267672 countsByYear W20792676722023 @default.
• W2079267672 crossrefType "journal-article" @default.
• W2079267672 hasAuthorship W2079267672A5024142413 @default.
• W2079267672 hasAuthorship W2079267672A5029283529 @default.
• W2079267672 hasAuthorship W2079267672A5032337653 @default.
• W2079267672 hasAuthorship W2079267672A5042809748 @default.
• W2079267672 hasAuthorship W2079267672A5064488553 @default.
• W2079267672 hasAuthorship W2079267672A5075794528 @default.
• W2079267672 hasAuthorship W2079267672A5091003529 @default.
• W2079267672 hasConcept C121608353 @default.
• W2079267672 hasConcept C126322002 @default.
• W2079267672 hasConcept C141071460 @default.
• W2079267672 hasConcept C2776694085 @default.
• W2079267672 hasConcept C2778405590 @default.
• W2079267672 hasConcept C2779598120 @default.
• W2079267672 hasConcept C2780456651 @default.
• W2079267672 hasConcept C2781413609 @default.
• W2079267672 hasConcept C29730261 @default.
• W2079267672 hasConcept C2992208098 @default.
• W2079267672 hasConcept C43376680 @default.
• W2079267672 hasConcept C526805850 @default.
• W2079267672 hasConcept C71924100 @default.
• W2079267672 hasConcept C90924648 @default.
• W2079267672 hasConceptScore W2079267672C121608353 @default.
• W2079267672 hasConceptScore W2079267672C126322002 @default.
• W2079267672 hasConceptScore W2079267672C141071460 @default.
• W2079267672 hasConceptScore W2079267672C2776694085 @default.
• W2079267672 hasConceptScore W2079267672C2778405590 @default.
• W2079267672 hasConceptScore W2079267672C2779598120 @default.
• W2079267672 hasConceptScore W2079267672C2780456651 @default.
• W2079267672 hasConceptScore W2079267672C2781413609 @default.
• W2079267672 hasConceptScore W2079267672C29730261 @default.
• W2079267672 hasConceptScore W2079267672C2992208098 @default.
• W2079267672 hasConceptScore W2079267672C43376680 @default.
• W2079267672 hasConceptScore W2079267672C526805850 @default.
• W2079267672 hasConceptScore W2079267672C71924100 @default.
• W2079267672 hasConceptScore W2079267672C90924648 @default.
• W2079267672 hasIssue "3" @default.
• W2079267672 hasLocation W20792676721 @default.
• W2079267672 hasLocation W20792676722 @default.
• W2079267672 hasOpenAccess W2079267672 @default.
• W2079267672 hasPrimaryLocation W20792676721 @default.
• W2079267672 hasRelatedWork W2012864969 @default.
• W2079267672 hasRelatedWork W2034027461 @default.
• W2079267672 hasRelatedWork W2047376960 @default.
• W2079267672 hasRelatedWork W2060713615 @default.
• W2079267672 hasRelatedWork W2078453319 @default.
• W2079267672 hasRelatedWork W2079416909 @default.
• W2079267672 hasRelatedWork W2401921527 @default.
• W2079267672 hasRelatedWork W2437002632 @default.
• W2079267672 hasRelatedWork W76690481 @default.
• W2079267672 hasRelatedWork W2151625869 @default.
• W2079267672 hasVolume "172" @default.
• W2079267672 isParatext "false" @default.
• W2079267672 isRetracted "false" @default.
• W2079267672 magId "2079267672" @default.
• W2079267672 workType "article" @default.